Hyponatremia is the most common electrolyte disorder in hospitalized patients. Many studies documented that it was related to increased morbidity and mortality in patients with congestive heart failure, liver cirrhosis, and neurologic diseases. Although knowledge of hyponatremia has been cumulated, the optimal manage ment of hyponatremia remains incompletely established in clinical practice because of the diversity of underlying disease states, and its multiple causes with differing pathophysiologic mechanisms. Since vasopressin receptor antagonists have unique aquaretic effect to selectively increase electrolytesfree water excretion, clinicians could apply a more effective method to treat hyponatremia. Tolvaptan has significant evidence that it improves serum sodium levels in patients with euvolemic or hypervolemic hyponatremia related with heart failure, cirrhosis or syndrome of inappropriate antidiuretic hormone. Tolvaptan has acceptable safety and tolerability for longterm usage in chronic hyponatremia, and the beneficial effects on serum Na + occurred in patients with both mild and marked hyponatremia.
Introduction
Hyponatremia is the most common electrolyte disorder in hospitalized patients 1, 2) . Many studies documented that it is related to increased morbidity and mortality in patients with congestive heart failure, liver cirrhosis, and neurologic diseases 36) . Although knowledge of hyponatremia has accumulated, the optimal management of hyponatremia remains incomplete in clinical practice because of the diversity of underlying disease states, and its multiple causes with differing pathophysiologic mechanisms. Since vasopressin receptor antagonists have unique aquaretic effect to selectively increase electrolytesfree water excretion, clinicians could apply a more effective method to treat hyponatremia. .
The vaptans are nonpeptide argininevasopressin
Arginine Vasopressin Receptors
V 1a Receptors
Vascular smooth muscle cells (in the myocardium), hepa tocytes and platelets have V 1a receptors that are activated by AVP or agonists, and lead to vasoconstriction in the coronary, peripheral circulation, and platelet aggregation 9) . Also, activated V 1a receptors cause an increase in intracellular calcium levels in cardiac myocytes and protein synthesis.
V 1a receptors are activated by a phosphoinositol signaling pathway.
V 1b Receptors
V 1b receptors are found in the anterior pituitary and have functions related to adrenocorticotropic hormone release 10) .
However the role of these receptors has not been found, yet.
The V 1b receptors, like the V 1a receptors, use a phosphoinositol signaling pathway 10) .
V 2 Receptors
The V 2 receptors are located on the collecting tubules of the kidney and have functions related to free water absorption by activating the aquaporin2 channel on the apical plasma membrane of the collecting duct cells 11) . Such antidiuretic function occurs through the adenylate cyclase signaling pathway with intracellular cyclic adenosine monophosphate as a second messenger, in the collecting duct cells 9, 11) .
Vasopressin Receptor Antagonists (VRAs)
Although AVP receptor antagonists were the first developed peptide antagonists in the 1960s and although animal studies showed that these peptides had an anti diuretic effect, several limitations of clinical use were found.
These peptides mediate a paradoxical weak agonism to the V 2 receptor and were seen in human studies to have poor oral bioavailability and short biological half lives 9) .
In 1992, the nonpeptide V 2 antagonist was first deve loped by Yamamura et al 12) . These nonpeptide VRAs had 
Tolvaptan
Tolvaptan is an orally active, nonpeptide, selective V 2 receptor antagonist 13) . It has about 2 times greater affinity for the V 2 receptor than native AVP and a 29fold greater selectivity for the V 2 receptors than the V 1a re ceptors 13, 14) . It is not related to V 1b receptors and also its metabolites have no activity at the V 2 receptor 13) . The effect of tolvaptan is to increase urine free water excretion causing decreased urine osmolality, and increased Na + concentration.
Pharmacokinetics
Following oral administration of tolvaptan, at least 40%
of an oral dose is absorbed; highly protein bound (99%), and reaches peak concentrations in 2 to 4 hours without any effects from food 13) . Its terminal phase halflife is 12 hours. CYP450
isoenzyme plays a role in its metabolism and its elimination is mainly nonrenal. Moderatetosevere hepatic impairment or congestive heart failure decreases the clearance and Patients were allowed to continue conventional therapy of heart failure (even diuretics), and if the Na + rose > 145 or > 12 mEq/L within 24 hours, the next dose of tolvaptan was stopped or decreased, or the investigators allowed the subjects to increase fluid intake. The increase in the average daily area under the curve (AUC) for the Na + concentration was significantly higher in the tolvaptan group than in the placebo group from baseline to study day 4, and day 30 (P < 0.001). In subgroup analysis categorized to mild hyponatremia (130 to 135 mEq/L) or marked hyponatremia (< 130 mEq/ L) at baseline, the tolvaptan group showed a significantly greater increase in the average daily AUC for the serum Na + concentration (P < 0.001). Within 8 hours after the first administration of tolvaptan, the serum Na + concentrations were significantly higher in the tolvaptan group than in the placebo group for both the total patient population and the subgroups categorized to degree of hyponatremia at baseline (all P < 0.01). Significantly more patients in the tolvaptan treated group had normal Na + values at 30 days than placebo (P < 0.001). Urine output was significantly greater in the tolvaptan groups in both studies (P < 0.001). The most common adverse events were thirst and dry mouth, and other adverse events included dizziness, hypotension, acute renal failure, sepsis, and ascites. After discontinuation of treatment, patients' Na + values decreased in both the tolvaptan and placebo groups and there was no statistical difference.
The long term use of tolvaptan in chronic hyponatremia 
Indications, Dosing, and Administration
Tolvaptan is indicated for patients with clinically significant euvolemic or hypervolemic hyponatremia defined as Na + < 125 mEq/L and also indicated for mild hyponatremia (Na + < 125-135 mEq/L) in symptomatic patients, including patients with heart failure, cirrhosis, and SIADH that has resisted conventional therapy in the U.S. 13) . However, in the European Union (EU), tolvaptan is approved for use in adults with hyponatraemia secondary to SIADH. Tolvaptan should not be used in patients requiring intervention to rapidly correct serum Na + to prevent or treat neurologic symptoms. The initiation of tolvaptan should only occur in a hospital setting to allow for monitoring of the therapeutic response and to avoid rapid correction of hyponatremia.
The usual initial dose of tolvaptan is 15 mg orally once daily without regard to meals. Dose adjustments can be made after at least 24 hours, up to a maximum of 60 mg daily.
Fluid restriction is not advised during the first 24 hours of therapy with the drug. Dosage adjustment according to age, gender, race, cardiac, mildtosevere renal or hepatic function is not needed. Tolvaptan has not been evaluated in patients with a creatinine clearance 10 mL/min or in patients undergoing dialysis. However, no benefit can be expected in anuric patients 13) .
Contraindication and Precautions
Tolvaptan, in patients with a need to rapidly correct serum Na + , with an inability to sense thirst or appropriately res pond to thirst, and hypovolemic hyponatremia, should be contraindicated 13) . Anuric patients have no clinical benefit of tolvaptan. The physician should take caution to avoid too rapid correction of serum Na + that may cause serious neurologic sequelae. Gastrointestinal bleeding more frequently occurs in liver cirrhosis patients receiving tolvaptan than in patients with placebo (10% vs. 2%) 13) .
Common adverse events of tolvaptan, defined as a 5% greater incidence than placebo, were thirst, dry mouth, asthenia, constipation, and pollakiuria 13) .
Drug Interactions
Tolvaptan is metabolized via CYP3A4. While CYP3A4 inducers, such as rifampin, decrease plasma concentrations of tolvaptan by 85%, strong inhibitors of CYP3A4, such as ketoconazole, clarithromycin, cyclosporine, tacrolimus, fluoxetine, amiodarone, cimetidine, and midazolam, increase plasma concentrations 1315) .
Conclusions
Through the SALT1,2, EVEREST, and SALTWATER studies, tolvaptan shows significant evidence that 1) it improves serum Na + levels patients with euvolaemic or hy pervolemic hyponatremia related with heart failure, cirrhosis or SIADH, 2) it has acceptable safety and tolerability for
